Major Pharmaceuticals and Avet Pharmaceuticals have recalled 25,814 tablets of Hydralazine HCl (25mg) because the medication failed quality tests for impurities and degradation during routine stability checks. Hydralazine is a prescription medication used to treat high blood pressure. While the risk is considered low, the product may not meet safety and quality specifications through its entire shelf life.
The tablets were found to have levels of impurities or degradation products that exceeded standard safety limits over time. This could potentially affect the medication's quality or expose patients to minor chemical breakdown products.
You have 2 options:
Distributed by Avet Pharmaceuticals Inc. and Major Pharmaceuticals.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.